Helicobacter pylori Archives | Be Korea-savvy
Home / Posts tagged Helicobacter pylori
Research Finds Acacia Honey Suppresses Helicobacter Pylori

Research Finds Acacia Honey Suppresses Helicobacter Pylori

SEOUL, May 25 (Korea Bizwire) – Researchers at the Rural Development Administration have discovered that acacia honey can inhibit the growth of helicobacter pylori, bacteria associated with a number of disorders of the upper gastrointestinal tract, including stomach ulcers, gastritis, and even stomach cancer.  Acacia honey, produced from false acacia trees or black locust flowers, [...]

RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection

RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection

TEL-AVIV, Israel, Jan. 10 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced first dosing in a three-way crossover pharmacokinetic (PK) study with RHB-105 [...]

RedHill Biopharma Reports Positive FDA Type B Meeting on RHB-105 for H. pylori Infection Ahead of Confirmatory Phase III Study

RedHill Biopharma Reports Positive FDA Type B Meeting on RHB-105 for H. pylori Infection Ahead of Confirmatory Phase III Study

TEL-AVIV, Israel, Nov. 10 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it has concluded a positive Type B Meeting with the U.S. [...]

RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead of Confirmatory Phase III Study for H. pylori Infection

TEL-AVIV, Israel, Jul. 21 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that it has received a Notice of Allowance from the United States Patent [...]

RedHill Biopharma Reports Successful Final Results of Phase III Study with RHB-105 for H. pylori Infection

RedHill Biopharma Reports Successful Final Results of Phase III Study with RHB-105 for H. pylori Infection

TEL-AVIV, Israel, Mar. 8 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced successful final results from the first Phase III clinical study with RHB-105 [...]